Voriconazole - A new therapeutic agent with an extended spectrum of antifungal activity

Clinical Microbiology and Infection

Volumn 10, Issue SUPPL. 1, 2004, Pages 107-117

  Donnelly, J P ^a   De Pauw, B E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antifungal treatment; Invasive fungal infection; Voriconazole

Indexed keywords

ACENOCOUMAROL; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ASTEMIZOLE; CARBAMAZEPINE; CIMETIDINE; CISAPRIDE; COUMARIN; CYCLOSPORIN; DIHYDROERGOTAMINE; ERGOT ALKALOID; ERGOTAMINE; FLUCONAZOLE; GLIBENCLAMIDE; GLIPIZIDE; MIDAZOLAM; PHENOBARBITAL; PHENPROCOUMON; PIMOZIDE; QUINIDINE; RANITIDINE; RAPAMYCIN; RIFAMPICIN; SULFONYLUREA; TACROLIMUS; TERFENADINE; TOLBUTAMIDE; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ACUTE KIDNEY FAILURE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; COLOR VISION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; FEVER; FLUSHING; FUSARIUM; HALLUCINATION; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; LIVER TOXICITY; METABOLIC DISORDER; MYCOSIS; NAUSEA; NEPHROTOXICITY; OBSTRUCTIVE JAUNDICE; PERIPHERAL EDEMA; PHOTOPHOBIA; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; SCEDOSPORIUM; SIDE EFFECT; SWEATING; TACHYCARDIA; TORSADE DES POINTES; VASODILATATION; VISUAL IMPAIRMENT; VOMITING; XEROSTOMIA;

FUSARIUM; SCEDOSPORIUM;

EID: 1642358518     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1470-9465.2004.00838.x     Document Type: Article

References (37)

1. Ghannoum MA, Kuhn DM. Voriconazole-better chances for patients with invasive mycoses. Eur J Med Res 2002; 7: 242-56.
2. Wildfeuer A, Seidl HP, Paule I, Haberreiter A. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses 1998; 41: 309-19.
3. Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother 2000; 44: 1734-6.
4. McGinnis MR, Nordoff N, Li RK, Pasarell L, Warnock DW. Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B. Med Mycol 2001; 39: 369-71.
5. Balian JD, Sukhova N, Harris JW et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995; 57: 662-9.
6. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71.
7. Chopra R, Fielding A, Goldstone AH. Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin (AmBisome)-a report on 40 cases from a single centre. Leuk Lymphoma 1992; 7 (Suppl.): 73-7.
8. Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989; 86: 791-800.
9. Mehta J, Kelsey S, Chu P et al. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. Bone Marrow Transplant 1997; 20: 39-43.
10. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995; 21: 1145-53.
11. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27: 603-18.
12. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
13. Ally R, Schürmann D, Kreisel W et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447-54.
14. Tomaszewski K, Purkins L. Visual effects with voriconazole [Abstract A-639]. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: American Society of Microbiology, 2001; 20.
15. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-34.
16. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 1997; 97: 663-5.
17. Tattevin P, Bruneel F, Lellouche F et al. Brain aspergillosis: Impact of azole therapy [Abstract M-869]. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA: American Society of Microbiology, 2002; 388.
18. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-31.
19. Nesky MA, McDougal EC, Peacock JE Jr. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis 2000; 31: 673-7.
20. Poza G, Montoya J, Redondo C et al. Meningitis caused by Pseudallescheria boydii treated with voriconazole. Clin Infect Dis 2000; 30: 981-2.
21. Tan KKC, Wood N, Weil A. Multiple-dose pharmacokinetics of voriconazole in chronic hepatic impairment [Abstract A-16]. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: American Society of Microbiology, 2001; 1.
22. Ghahramani P, Purkins L, Kleinermans D et al. Effects of rifampicin and rifabutin on the pharmacokinetics of voriconazole [Abstract 844]. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ont.: American Society of Microbiology, 2000: 23.
23. Romero AJ, Pogamp PL, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002; 71: 226-34.
24. Wood N, Tan K, Allan R et al. Effect of Voriconazole on the pharmacokinetics of tacrolimus [Abstract A-20]. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: American Society of Microbiology, 2001; 2.
25. Singh N, Zhang S, Gayowski T, Venkataramanan R. Voriconazole inhibition of tacrolimus metabolism after liver transplantation and in human liver microsomes [Abstract A-21]. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: American Society of Microbiology, 2001; 2.
26. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol 2003; 56 (Suppl. 1): 24-9.
27. Ghahramani P, Purkins L, Kleinermans D et al. The pharmacokinetics of voriconazole and its effect on prednisolone disposition [Abstract 842]. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ont.: American Society of Microbiology, 2000: 23.
28. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole does not affect the steady-state pharmacokinetics of digoxin. Br J Clin Pharmacol 2003; 56 (Suppl. 1): 45-50.
29. Wood N, Abel S, Fielding A et al. Voriconazole does not affect the pharmacokinetics of mycophenolic acid [Abstract A-24]. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: American Society of Microbiology, 2001; 3.
30. Purkins L, Wood N, Ghahramani P et al. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003; 56; (Suppl. 1): 37-44.
31. Wood N, Tan K, Purkins L et al. Effect of omeprazole on the steady state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003; 56 (suppl. 1): 56-61.
32. Wood N, Tan K, Allan R et al. Effect of voriconazole on the pharmacokinetics of omeprazole [Abstract A-19]. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL: American Society of Microbiology, 2001; 2.
33. Purkins L, Wood N, Kleinermans D, Love ER. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. Br J Clin Pharmacol 2003; 56 (Suppl. 1): 62-8.
34. Tomaszewski K, Nurbhai N, Baruch A. The overall clinical safety of voriconazole [Abstract 123]. Presented at the Tandem BMT Meetings, Orlando, FL, USA. Biol Blood Marrow Transplant 2002; 8: 95-6.
35. Denning DW, Lee JY, Hostetler JS et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135-44.
36. Caillot D, Bassaris H, McGeer A et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001; 33: e83-90.
37. Caillot D. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Acta Haematol 2003; 109: 111-18.